FDA to Review DUPIXENT(R) (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma

TARRYTOWN, N.Y. and PARIS, March 2, 2018 -- (Healthcare Sales & Marketing Network) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biolo... Biopharmaceuticals, FDA Regeneron Pharmaceuticals, Sanofi, DUPIXENT, dupilumab, asthma

http://salesandmarketingnetwork.com/news_release_bs.html?ID=2043574

Source: HSMN NewsFeed - March 2, 2018 Category: Pharmaceuticals Source Type: news

More News: Asthma | Food and Drug Administration (FDA) | Marketing | Pharmaceuticals